Vitronectin in host pathogen interactions and antimicrobial therapeutic applications

Central European Journal of Biology

Volumn 6, Issue 6, 2011, Pages 973-980

  Singh, Birendra ^a   Su, Yu Ching ^a   Riesbeck, Kristian ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bacteria; Complement system; Extracellular matrix; Innate immunity; Integrins; Vitronectin

Indexed keywords

BACTERIA (MICROORGANISMS); EUKARYOTA;

EID: 81755161453     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-011-0077-x     Document Type: Review

References (68)

1. Preissner K. T., Seiffert D., Role of vitronectin and its receptors in haemostasis and vascular remodeling, Thromb. Res., 1998, 89, 1-21.
2. Yeh W. L., Lu D. Y., Liou H. C., Fu W. M., A forward loop between glioma and microglia: Glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells, J. Cell Physiol., 2011, DOI: 10. 1002/jcp. 22746.
3. Ekmekci O. B., Ekmekci H., Vitronectin in atherosclerotic disease, Clin. Chim. Acta., 2006, 368, 77-83.
4. Xiao J., Natarajan K., Rajala M. S., Astley R. A., Ramadan R. T., Chodosh J., Vitronectin: a possible determinant of adenovirus type 19 tropism for human corneal epithelium, Am. J. Ophthalmol., 2005, 140, 363-369.
5. Zipfel P. F., Skerka C., Complement regulators and inhibitory proteins, Nat. Rev. Immunol., 2009, 9, 729-740.
6. Chhatwal G. S., Preissner K. T., Muller-Berghaus G., Blobel H., Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli, Infect. Immun., 1987, 55, 1878-1883.
7. Singh B., Su Y. C., Riesbeck K., Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion, Mol. Microbiol., 2010, 78, 545-560.
8. Bergmann S., Lang A., Rohde M., Agarwal V., Rennemeier C., Grashoff C., et al., Integrinlinked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells, J. Cell Sci., 2009, 122, 256-267.
9. Sa E. C. C., Griffiths N. J., Virji M., Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells, PLoS Pathog., 2010, 6, e1000911.
10. Preissner K. T., Structure and biological role of vitronectin, Annu. Rev. Cell. Biol., 1991, 7, 275-310.
11. Peterson C. B., Binding sites on native and multimeric vitronectin exhibit similar affinity for heparin the influence of self-association and multivalence on ligand binding, Trends Cardiovasc. Med., 1998, 8, 124-131.
12. Zhuang P., Chen A. I., Peterson C. B., Native and multimeric vitronectin exhibit similar affinity for heparin. Differences in heparin binding properties induced upon denaturation are due to self-association into a multivalent form, J. Biol. Chem., 1997, 272, 6858-6867.
13. Volker W., Hess S., Vischer P., Preissner K. T., Binding and processing of multimeric vitronectin by vascular endothelial cells, J. Histochem. Cytochem., 1993, 41, 1823-1832.
14. Blouse G. E., Dupont D. M., Schar C. R., Jensen J. K., Minor K. H., Anagli J. Y., et al., Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements, Biochemistry, 2009, 48, 1723-1735.
15. Minor K. H., Peterson C. B., Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix, J. Biol. Chem., 2002, 277, 10337-10345.
16. Underwood P. A., Kirkpatrick A., Mitchell S. M., New insights into heparin binding to vitronectin: studies with monoclonal antibodies, Biochem. J., 2002, 365, 57-67.
17. Peake P. W., Greenstein J. D., Pussell B. A., Charlesworth J. A., The behaviour of human vitronectin in vivo: effects of complement activation, conformation and phosphorylation, Clin. Exp. Immunol., 1996, 106, 416-422.
18. Mondino A., Blasi F., uPA and uPAR in fibrinolysis, immunity and pathology, Trends Immunol., 2004, 25, 450-455.
19. Haiko J., Laakkonen L., Juuti K., Kalkkinen N., Korhonen T. K., The omptins of Yersinia pestis and Salmonella enterica cleave the reactive center loop of plasminogen activator inhibitor 1, J. Bacteriol., 2010, 192, 4553-4561.
20. Renckens R., Roelofs J. J., Bonta P. I., Florquin S., de Vries C. J., Levi M., et al., Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia, Blood, 2007, 109, 1593-1601.
21. Lijnen H. R., Pleiotropic functions of plasminogen activator inhibitor-1, J. Thromb. Haemost., 2005, 3, 35-45.
22. Keates A. C., Tummala S., Peek R. M., Jr., Csizmadia E., Kunzli B., Becker K., et al., Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells, Infect. Immun., 2008, 76, 3992-3999.
23. Chung M. C., Jorgensen S. C., Popova T. G., Tonry J. H., Bailey C. L., Popov S. G., Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection, J. Med. Microbiol., 2009, 58, 737-744.
24. Urano T., Ihara H., Umemura K., Suzuki Y., Oike M., Akita S., et al., The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis Cleaves and inactivates plasminogen activator inhibitor type 1, J. Biol. Chem., 2001, 276, 24690-24696.
25. Beaufort N., Seweryn P., de Bentzmann S., Tang A., Kellermann J., Grebenchtchikov N., et al., Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa, Biochem. J., 2010, 428, 473-482.
26. Beaufort N., Wojciechowski P., Sommerhoff C. P., Szmyd G., Dubin G., Eick S., et al., The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin, Biochem. J., 2008, 410, 157-165.
27. Kapur V., Topouzis S., Majesky M. W., Li L. L., Hamrick M. R., Hamill R. J., et al., A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin, Microb. Pathog., 1993, 15, 327-346.
28. Janoir C., Pechine S., Grosdidier C., Collignon A., Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins, J. Bacteriol., 2007, 189, 7174-7180.
29. Blom A. M., Hallstrom T., Riesbeck K., Complement evasion strategies of pathogens-acquisition of inhibitors and beyond, Mol. Immunol., 2009, 46, 2808-2817.
30. Hallstrom T., Blom A. M., Zipfel P. F., Riesbeck K., Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance, J. Immunol., 2009, 183, 2593-2601.
31. Hallstrom T., Trajkovska E., Forsgren A., Riesbeck K., Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin, J. Immunol., 2006, 177, 430-436.
32. Singh B., Jalalvand F., Morgelin M., Zipfel P., Blom A. M., Riesbeck K., Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex, Mol. Microbiol., 2011, 81, 80-98.
33. Leduc I., Olsen B., Elkins, C., Localization of the domains of the Haemophilus ducreyi trimeric autotransporter DsrA involved in serum resistance and binding to the extracellular matrix proteins fibronectin and vitronectin, Infect. Immun., 2009, 77, 657-666.
34. Attia A. S., Ram S., Rice P. A., Hansen E. J., Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade, Infect. Immun., 2006, 74, 1597-1611.
35. Singh B., Blom A. M., Unal C., Nilson B., Morgelin M., Riesbeck K., Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity, Mol. Microbiol., 2010, 75, 1426-1444.
36. Dehio M., Gomez-Duarte O. G., Dehio C., Meyer T. F., Vitronectin-dependent invasion of epithelial cells by Neisseria gonorrhoeae involves alpha(v) integrin receptors, FEBS Lett., 1998, 424, 84-88.
37. Isberg R. R., Tran van Nhieu G., Binding and internalization of microorganisms by integrin receptors, Trends Microbiol., 1994, 2, 10-14.
38. Liang O. D., Rosenblatt S., Chhatwal G. S., Preissner K. T., Identification of novel heparin-binding domains of vitronectin, FEBS Lett., 1997, 407, 169-172.
39. Milis L., Morris C. A., Sheehan M. C., Charlesworth J. A., Pussell B. A., Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9, Clin. Exp. Immunol., 1993, 92, 114-119.
40. Sheehan M., Morris C. A., Pussell B. A., Charlesworth J. A., Complement inhibition by human vitronectin involves non-heparin binding domains, Clin. Exp. Immunol., 1995, 101, 136-141.
41. Tschopp J., Masson, D., Schafer, S., Peitsch, M., Preissner K. T., The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities, Biochemistry, 1988, 27, 4103-4109.
42. Schmidtchen A., Frick I. M., Andersson E., Tapper H., Bjorck L., Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37, Mol. Microbiol., 2002, 46, 157-168.
43. Schmidtchen A., Frick I. M., Bjorck L., Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin, Mol. Microbiol., 2001, 39, 708-713.
44. Andersson E., Rydengard V., Sonesson A., Morgelin M., Bjorck L., Schmidtchen A., Antimicrobial activities of heparin-binding peptides, Eur. J. Biochem., 2004, 271, 1219-1226.
45. Malmsten M., Davoudi M., Schmidtchen A., Bacterial killing by heparin-binding peptides from PRELP and thrombospondin, Matrix Biol., 2006, 25, 294-300.
46. Cardin A. D., Weintraub H. J., Molecular modeling of protein-glycosaminoglycan interactions, Arteriosclerosis, 1989, 9, 21-32.
47. Fromm J. R., Hileman R. E., Caldwell E. E., Weiler J. M., Linhardt R. J., Pattern and spacing of basic amino acids in heparin binding sites, Arch. Biochem. Biophys., 1997, 343, 92-100.
48. Vila J., Soriano A., Mensa J., [Molecular basis of microbial adherence to prosthetic materials. Role of biofilms in prosthesis-associated infection], Enferm. Infecc. Microbiol. Clin., 2008, 26, 48-54; quiz 55 (in Spanish).
49. Darouiche R. O., Treatment of infections associated with surgical implants, N. Engl. J. Med., 2004, 350, 1422-1429.
50. Narasimhan C., Lai C. S., Conformational changes of plasma fibronectin detected upon adsorption to solid substrates: a spin-label study, Biochemistry, 1989, 28, 5041-5046.
51. Wolff C., Lai C. S., Fluorescence energy transfer detects changes in fibronectin structure upon surface binding, Arch. Biochem. Biophys., 1989, 268, 536-545.
52. Lundberg F., Schliamser S., Ljungh A., Vitronectin may mediate staphylococcal adhesion to polymer surfaces in perfusing human cerebrospinal fluid, J. Med. Microbiol., 1997, 46, 285-296.
53. Cagavi F., Akalan N., Celik H., Gur D., Guciz B., Effect of hydrophilic coating on microorganism colonization in silicone tubing, Acta Neurochir. (Wien), 2004, 146, 603-610.
54. Glinel K., Jonas A. M., Jouenne T., Leprince J., Galas L., Huck W. T., Antibacterial and antifouling polymer brushes incorporating antimicrobial peptide, Bioconjug. Chem., 2009, 20, 71-77.
55. de Carvalho C. C., Biofilms: recent developments on an old battle, Recent Pat. Biotechnol., 2007, 1, 49-57.
56. Jose B., Antoci V., Jr., Zeiger A. R., Wickstrom E., Hickok N. J., Vancomycin covalently bonded to titanium beads kills Staphylococcus aureus, Chem. Biol., 2005, 12, 1041-1048.
57. Kilic D., Agalar C., Ozturk E., Denkbas E. B., Cime A., Agalar F., Antimicrobial activity of cefazolin-impregnated mesh grafts, ANZ. J. Surg., 2007, 77, 256-260.
58. Leung D., Spratt D. A., Pratten J., Gulabivala K., Mordan N. J., Young, A. M., Chlorhexidinereleasing methacrylate dental composite materials, Biomaterials, 2005, 26, 7145-7153.
59. Ravikumar, T., Murata, H., Koepsel, R. R. and Russell, A. J., Surface-active antifungal polyquaternary amine, Biomacromolecules, 2006, 7, 2762-2769.
60. Costa, F., Carvalho, I. F., Montelaro, R. C., Gomes, P. and Martins, M. C., Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces, Acta Biomater., 2011, 7, 1431-1440.
61. Aaboe M., Offersen B. V., Christensen A., Andreasen P. A., Vitronectin in human breast carcinomas, Biochim. Biophys. Acta, 2003, 1638, 72-82.
62. Bloemendal H. J., de Boer H. C., Koop E. A., van Dongen A. J., Goldschmeding R., Landman W. J., et al., Activated vitronectin as a target for anticancer therapy with human antibodies, Cancer Immunol. Immunother., 2004, 53, 799-808.
63. Li D. Q., Lundberg F., Ljungh A., Characterization of vitronectin-binding proteins of Staphylococcus epidermidis, Curr. Microbiol., 2001, 42, 361-367.
64. Nydegger U. E., Rieben R., Aeschbacher B., Biocompatibility of apheresis harness, Transfus. Sci., 1990, 11, 43-54.
65. Salama A., Hugo F., Heinrich D., Hoge R., Muller R., Kiefel V., et al., Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass, N. Engl. J. Med., 1988, 318, 408-414.
66. Lundberg F., Lea T., Ljungh A., Vitronectin-binding staphylococci enhance surface-associated complement activation, Infect. Immun., 1997, 65, 897-902.
67. Lundberg F., Li D. Q., Falkenback D., Lea T., Siesjo P., Soderstrom S., et al., Presence of vitronectin and activated complement factor C9 on ventriculoperitoneal shunts and temporary ventricular drainage catheters, J. Neurosurg., 1999, 90, 101-108.
68. Liang O. D., Preissner K. T., Chhatwal G. S., The hemopexin-type repeats of human vitronectin are recognized by Streptococcus pyogenes, Biochem. Biophys. Res. Commun., 1997, 234, 445-449.